CClinicalTrials.gg
CompletedNCT02769741Updated Nov 1, 2016

A Controlled-Feeding Study to Assess the Effect of Cashews on Fasting Lipoprotein Levels

An interventional study of Cashews followed by Control and Control followed by Cashews in Healthy Volunteers, sponsored by Kraft Heinz Company. Completed. Open to participants aged 21 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-01.

Sponsored by Kraft Heinz Company · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
21 Years to 79 Years
Sex
All
01

Study summary

This study will assess the nutritional effect of cashews on LDL-C concentrations and secondarily on other aspects of the fasting lipoprotein lipid profile in healthy men and women with moderately elevated cholesterol.

Read the detailed description

This trial will utilize a randomized, two-period crossover design to examine the effects of cashew consumption on LDL-C and other aspects of the fasting lipoprotein lipid profile in healthy, moderately hyper-cholesterolemic individuals consuming a typical "American diet." Two arms consisting of two 28-day controlled-feeding treatment periods will allow for an isocaloric comparison of a diet with or without cashews.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Cashew
  • Lipoprotein
03

In context

Lead sponsor

This is the only study on the registry with Kraft Heinz Company as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • BMI of ≥18.00 and ≤32.00 kg/m\^2
  • Fasting LDL-C level ≥130 mg/dL and \<200 mg/dL
  • Fasting TG ≤350 mg/dL

Exclusion criteria

Exclusion Criteria:

  • CHD or CHD risk equivalent
  • Pregnancy
  • Use of lipid altering medications which cannot be stopped
  • Certain liver, kidney, lung, or gastrointestinal conditions
  • Poorly controlled hypertension
  • Certain medications
  • Allergy or sensitivity to nuts or other food/beverage or food/beverage component
  • Active cancers treated within prior 2 years (except non-melanoma skin cancer)
  • Significant weight loss or gain within prior 3 months
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Other
    Crossover 1: Control Diet followed by Active Diet

    Treatment Period 1: Controlled diet without cashew nuts; Treatment Period 2: Controlled diet with cashew nuts

    Other: Control followed by Cashews

  • Other
    Crossover 2: Active Diet followed by Control Diet

    Treatment Period 1: Controlled diet with cashew nuts; Treatment Period 2: Controlled diet without cashew nuts

    Other: Cashews followed by Control

Interventions

  • OtherCashews followed by Control

    Participants will receive the active diet with cashew nuts as a daily snack during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the control diet at the same calorie level, but with a control snack instead of cashew nuts during Test Period II.

  • OtherControl followed by Cashews

    Participants will receive a controlled diet without cashew nuts during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the active diet at the same calorie level, but with cashew nuts as a daily snack during Test Period II.

06

What researchers measure

Primary outcomes

  1. Change in LDL-C concentration measured in blood

    Time frame: % change from baseline (day 0) to the end of the test period (day 28) for Test Period I and II.

Secondary outcomes

  1. Total cholesterol change

    Time frame: % change from baseline (day 0) to the end of the test period (day 28) for Test Period I and II.

  2. HDL-cholesterol change

    Time frame: % change from baseline (day 0) to the end of the test period (day 28) for Test Period I and II.

  3. Non-HDL-cholesterol change

    Time frame: % change from baseline (day 0) to the end of the test period (day 28) for Test Period I and II.

  4. Triglyceride change

    Time frame: % change from baseline (day 0) to the end of the test period (day 28) for Test Period I and II.

  5. Total cholesterol/HDL-cholesterol ratio change

    Time frame: % change from baseline (day 0) to the end of the test period (day 28) for Test Period I and II.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Mah E, Schulz JA, Kaden VN, Lawless AL, Rotor J, Mantilla LB, Liska DJ. Cashew consumption reduces total and LDL cholesterol: a randomized, crossover, controlled-feeding trial. Am J Clin Nutr. 2017 May;105(5):1070-1078. doi: 10.3945/ajcn.116.150037. Epub 2017 Mar 29. PubMed 28356271 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02769741
Lead sponsor
Kraft Heinz Company
Collaborators
BioFortis
Responsible party
Sponsor
First posted
May 12, 2016
Start date
Jan 2016
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Nov 1, 2016

Study contacts

Andrea Lawless, MD
principal investigator · BioFortis

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion